The company will offer access to Galleri®, an innovative blood test from GRAIL, Inc. that screens for more than 50 types of cancer
SAN FRANCISCO–(BUSINESS WIRE)–Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a simple cancer screening blood test that can detect a signal for 50+ types of cancer even before symptoms appear1. This multi-cancer early detection (MCED) test combines Hims & Hers’ scale with GRAIL’s innovative cancer screening technology to dramatically increase access to proactive care.
More than one in three people will develop cancer in their lifetime2, but many cancers can go undetected for longer than necessary, especially before symptoms arise. While recommended screenings can catch breast, cervical, colorectal, prostate, and lung cancers early, other aggressive cancers, like pancreatic and ovarian, are often discovered at later stages when treatment is harde,r and outcomes may be worse. With advances like Galleri® that make cancer screening more accessible, this doesn’t need to be the case.
The Hims & Hers Multi-Cancer Test by Galleri® looks for a shared signal of 50+ types of cancer, including those without recommended screenings. In addition to recommended screenings, this simple blood test can be taken annually and enables customers to proactively screen for cancers that can develop even before symptoms.
“Even though cancer screening technology has advanced significantly, there are still too many life-changing diagnoses that should have been made earlier. Access to innovation is the key to changing that,” said Andrew Dudum, co-founder and CEO at Hims & Hers. “World-class care should be available to everyone, not just those with the time and resources to navigate the traditional system. Our platform brings together the best the healthcare industry has to offer in order to close the access gap, and our work with GRAIL is a critical part of delivering cutting-edge care to everyone.”
Galleri’s cutting-edge technology powers early detection of cancer signals in blood, including a prediction of where in the body the signal is likely coming from. The Galleri test does not detect all cancers, and false positive and false negative results can occur.
“Hims & Hers is at the forefront of making healthcare more attainable and impactful for those who want to take control of their health,” said Josh Ofman, MD, MSHS, President at GRAIL. “GRAIL believes making validated MCED tests available as a complement to recommended cancer screenings can help to increase cancer detection before cancers spread, improve outcomes, and enable this breakthrough technology to be available to more people. As a leader in digital health solutions, Hims is a natural partner to offer the Galleri test, helping bring personalized, innovative healthcare to a broader population.”
“We know that cancers found early, before they’ve spread, can potentially have better outcomes than those caught later after the cancer has spread,” said Dr. Pat Carroll, Chief Medical Officer at Hims & Hers. “With access to this new, innovative screening technology, we’re empowering customers to tackle health challenges when treatment can be more manageable and more successful. This is a meaningful step toward helping people live happier, healthier lives.”
Starting today, Hims & Hers customers can add the Multi-Cancer Test by Galleri® onto existing Labs plans3 at a $250 discount to the Galleri list price4. For more information, visit hims.com/labs/cancer-test and forhers.com/labs/cancer-test.
Media Kit
About Hims & Hers Health, Inc.
Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe that how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory/Test Information
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
1 Klein, E. A., Richards, D., Cohn, A., Tummala, M., Lapham, R., Cosgrove, D., Chung, G., Clement, J., Gao, J., Hunkapiller, N., Jamshidi, A., Kurtzman, K. N., Seiden, M. V., Swanton, C., & Liu, M. C. (2021). Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of oncology: official journal of the European Society for Medical Oncology, 32(9), 1167–1177.
3 Not available in all 50 states. Eligibility and Rx required. The test is not FDA-approved. Use is recommended for adults with an elevated risk for cancer, such as those 50 and older. The test is a screening test that looks for a signal sometimes associated with cancer. It does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The test does not detect a signal for all cancers, and not all cancers can be detected in the blood. False positive and false negative results do occur. The test should be used in addition to healthcare provider-recommended screening tests. We recommend talking to your healthcare provider to determine if additional testing is needed. For more important safety and laboratory/test information, please click here.
4 You must be a Labs by Hims & Hers customer to purchase the multi-cancer test. The multi-cancer test subscription and your Labs subscription will become one bundled subscription that renews on the date that Labs was purchased. If the multi-cancer test is purchased after Labs, the subscription will renew in less than 365 days.
Contacts
Abby Reisinger-Moley
press@forhims.com
